The spectrum of antecedent infections in Guillain-Barre syndrome: A case-control study

Neurology

Volumn 51, Issue 4, 1998, Pages 1110-1115

  Jacobs, B C ^a   Rothbarth, P H ^a   Van Der Meche F G A ^a   Herbrink, P ^c   Schmitz, P I M ^b   De Klerk, M A ^a   Van Doorn, P A ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c REINIER DE GRAAF HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GANGLIOSIDE ANTIBODY;

ADENOVIRUS; ADULT; ARTICLE; BACTERIAL INFECTION; CAMPYLOBACTER JEJUNI; CASE CONTROL STUDY; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; EPSTEIN BARR VIRUS; FEMALE; GRAM NEGATIVE INFECTION; GUILLAIN BARRE SYNDROME; HAEMOPHILUS INFLUENZAE; HERPES SIMPLEX VIRUS; HUMAN; INFLUENZA VIRUS A; INFLUENZA VIRUS B; MAJOR CLINICAL STUDY; MALE; MYCOPLASMA PNEUMONIAE; PARAINFLUENZA VIRUS; PRIORITY JOURNAL; VARICELLA ZOSTER VIRUS; VIRUS INFECTION;

EID: 0031665065     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.51.4.1110     Document Type: Article

References (27)

1. Leneman F. The Guillain-Barré syndrome. Arch Intern Med 1966;118:139-144.
2. Winer JB, Hughes RAC, Anderson MJ, Jones DM, Kangro H, Watkins RPF. A prospective study of acute idiopathic neuropathy. II. Antecedent events. J Neurol Neurosurg Psychiatry 1988;51:613-618.
3. Mishu B, Ilyas AA, Koski CL, et al. Serologic evidence of previous Campylobacter jejuni infection in patients with the Guillain-Barré syndrome. Ann Intern Med 1993;118:947-953.
4. Rees JH, Soudain SE, Gregson NA, Hughes RAC. Campylobacter jejuni infection in Guillain-Barré syndrome. N Engl J Med 1995;333:1374-1379.
5. Rees JH, Gregson NA, Hughes RAC. Anti-ganglioside GM1 antibodies in Guillain-Barré syndrome and their relationship to Campylobacter jejuni infection. Ann Neurol 1995;38:809-816.
6. Jacobs BC, van Doom PA, Schmitz PIM, et al. Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome. Ann Neurol 1996;40:181-187.
7. Irie S, Saito T, Nakamura K, et al. Association of anti-GM2 antibodies in Guillain-Barré syndrome with acute cytomegalovirus infection. J Neuroimmunol 1996;68:19-26.
8. Jacobs BC, van Doom PA, Groeneveld JHM, Tio-Gillen AP, van der Meché FGA. Cytomegalovirus infections and anti-GM2 antibodies in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1997;62:641-643.
9. Visser LH, van der Meché FGA, Meulstee J, et al. Cytomegalovirus infection and Guillain-Barré syndrome: the clinical, electrophysiological, and prognostic features. Neurology 1996; 47:668-673.
10. Goldschmidt B, Menonna J, Fortunato J, Dowling P, Cook SD. Mycoplasma antibody in Guillain-Barré syndrome and other neurological disorders. Ann Neurol 1980;7:108-112.
11. Dowling PC, Cook SD. Role of infection in Guillain-Barré syndrome: laboratory confirmation of herpesviruses in 41 cases. Ann Neurol 1981;9(suppl):44-55.
12. Van der Meché FGA, Schmitz PIM, the Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992;326:1123-1129.
13. The Dutch Guillain-Barré Study Group. Treatment of Guillain-Barré syndrome with high-dose immune globulins combined with methylprednisolone: a pilot study. Ann Neurol 1994;35:749-752.
14. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990; 27(suppl):21-24.
15. Fleiss JL. Statistical methods for rates and proportions, ch. 8. New York: John Wiley, 1981.
16. Breslow NE, Day NE. Statistical methods in cancer research, vol. 1. The analysis of case-control studies. Lyon, France: IARC, 1980.
17. Ogawa-Goto K, Funamoto N, Ohta Y, Abe T, Nagashima K. Myelin gangliosides of human peripheral nervous system: an enrichment of GM1 in the motor nerve myelin isolated from cauda equina. J Neurochem 1992;59:1844-1849.
18. Boucquey D, Sindic CJM, Lamy M, Delmée M, Tomasi JP, Laterre EC. Clinical and serological studies in a series of 45 patients with Guillain-Barré syndrome. J Neurol Sci 1991; 104:56-63.
19. Ogawa-Goto K, Kubota K, Kurotani A, Abe T. Antibodies against sulfated glycosphingolipids of peripheral nerve myelins detected in patients with human cytomegalovirus infection. J Neuroimmunol 1994;55:55-60.
20. Van den Berg LH, Lankamp CLAM, de Jager AEJ, et al. Anti-sulfatide antibodies in peripheral neuropathy. J Neurol Neurosurg Psychiatry 1993;56:1164-1168.
21. Kusunoki S, Chiba A, Hitoshi S, Takizawa H, Kanazawa I. Anti-Gal-C antibody in autoimmune neuropathies subsequent to mycoplasma infection. Muscle Nerve 1995;18:409-413.
22. Westall FC, Root-Bernstein R. Cause and prevention of postinfectious and postvaccinal neuropathies in light of a new theory of autoimmunity. Lancet 1986;i:251-252.
23. Willison HJ, Veitch J. Immunoglobulin subclass distribution and binding characteristics of anti-GQ1b antibodies in Miller Fisher syndrome. J Neuroimmunol 1994;50:159-165.
24. Willison HJ, O'Hanlon GM, Paterson GJ, et al. A somatically mutated human anti-ganglioside antibody that induces experimental neuropathy in mice is encoded by the variable region heavy chain gene, V1-18. J Clin Invest 1996;97:1155-1164.
25. Yuki N, Taki T, Inagaki F, et al. A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure. J Exp Med 1993;178:1771-1775.
26. Suzuki S, Kawaguchi M, Mizuno K, Takama K, Yuki N. Immunological properties and ganglioside recognition by Campylobacter jejuni-enterotoxin and cholera toxin. FEMS Immunol Med Microbiol 1994;8:207-212.
27. Loomes LM, Uemura K, Childs RA, et al. Erythrocyte receptors for Mycoplasma pneumoniae are sialylated oligosaccharides of Ii antigen type. Nature 1984;307:560-563.